| 摘要 |
<p>The present invention relates to a pharmaceutical use of STIM1, wherein a C-terminal of STIM1, which is a SERCA1a-binding region (STIM1-SBR: a 449-671 amino acid sequence region), inhibits activities of a ryanodine receptor calcium channel. Accordingly, by using the STIM1 or a STIM1-SBR inhibitor, the total quantity of STIM1 proteins is adjusted, and a decrease in activities of the ryanodine receptor calcium channel is inhibited. Also, skeletal muscle contraction is promoted, thereby preventing or treating diseases related to hypotonus including skeletal muscle contraction disorders.</p> |
